Skip to main content

Table 1 Fourteen microarray-based human lung cancer microRNA expression profiling studies (lung cancer tissue versus normal)

From: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues

First author (reference) Year Lung cancer patients Differentially expressed miRNAs
   Origin Period Cancer type Clinical Stage No. of collected tissue samples (cancer/normal) Platform Cut-off criteria Total Up-regulated features Down-regulated features
Boeri [19] 2011 Italy Jun 2000 to Jun 2006 Lung cancer Satge I to IV (Stage I 60%) 52 (28/24) The miRNA microarray (Ohio State University, version 2.0) P < 0.001 56 6 4
Dacic [20] 2010 USA (Pittsburgh) NR ADC NR 12 (6/6) FlexmiR human microRNA pool (Version 8, Exiqon, Vedbaek, Denmark) FC > 20 7 4 3
Gao [21] 2010 China (Jiangsu, First Affiliated Hospital of Nanjing Medical University) Apr 2008 to Sep 2008 NSCLC NR 16 (8/8) miRCURY™ LNA microRNA Arrays (version 10.0, Exiqon, Vedbaek, Denmark) FC > 2, P < 0.05 27 9 18
    Apr 2008 SCC [Ref 33] NR 8 (4/4)   FC > 2 31 7 23
Jang [22] 2012 USA (Minnesota) Jan 1997 to Sep 2008 ADC Stage I to IV (Stage I 68.0%) 206 (103/103) Illumina MicroRNA Profiling FC > 1.5, P < 0.01, DR < 0.05 20 10 10
Ma [23] 2011 China (Zhejiang) NR NSCLC (SCC:3; ADC:3) Stage I to IV (Stage I 16.7%) 12 (6/6) Illuminia Technologies “humanMI_V2” FDR <0.1 1 1 0
Raponi [24] 2009 USA (Michigan) Oct 1991 to Jul 2002 SCC Stage I to IV (Stage I 55%) 71 (61/10) Ambion mirVana Bioarray (version 2.0) Signal intensity (log2) >6 in at least one group 15 13 2
Seike [25] 2009 USA (Baltimore: 15; Minnesota:7); Japan (Hamamatsu: 6) 2000 to 2004 NSCLC (ADC around 78%) Stage I to IV (Stage I 75%) 56 (28/28) The miRNA microarray (Ohio State University, version 3.0) P < 0.01, FDR <0.15 18 5 13
Tan [26] 2011 China (Beijing) 2000 to 2002 SCC NR 68 (34/34) CapitalBio platform (CapitalBio Corp.) Significance analysis of microarray 22 12 10
Võsa [27] 2011 Estonia (Tartu) 2002 to 2008 NSCLC (SCC:18; ADC:20) Stage I/II (Stage I 92%) 65 (38/27) Illumina MicroRNA Profiling BeadChip FC > 2, P < 0.01 60 31 29
Wang [28] 2011 China (Jiangsu, Nanjing Chest Hospital) 2006 to 2008 NSCLC (SCC:7; ADC:16) NR 46 (23/23) μParaflo microfluidic chip technology (Atactic Technologies, Houston, TX, USA) FC > 5, P < 0.01 40 27 13
Xing [29] 2010 USA (Baltimore) Mar 2000 to Jun 2003 SCC Stage I 30 (15/15) GeneChipR miRNA Array (Affymetrix, Santa Clara, CA, USA) FC > 1.5, P < 0.01 25 7 18
Yanaihara [30] 2006 USA (Baltimore) 1990 to 1999 NSCLC (SCC:39; ADC:65,) Stage I to IV (Stage I 62.5%) 208 (104/104) The miRNA microarray Chip (TJU version 1.1) P < 0.001 43 15 28
     SCC   78 (39/39)    16 10 6
     ADC   130 (65/65)    17 5 12
Yang [31] 2010 China (Shaanxi) NR SCC NR 6 (3/3) miRCURY™ LNA array (version 10.0, Exiqon, Vedbaek, Denmark) FC > 1.5, P < 0.05 9 2 7
Yu [32] 2010 USA (Baltimore) NR ADC Stage I 40 (20/20) Taqman human miRNA array A (System Biosciences, Mountain View, CA) FC > 1.5, P < 0.01 20 11 9
  1. Abbreviations: ADC, adenocarcinoma/adenosquamous carcinoma; FC, fold change; FDR, false discovery rate; miRNAs, microRNAs; NR, not reported; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.
  2. Only the top ten miRNAs of the identified 56 significantly differentially expressed miRNAs were provided.